This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martino, S. Articles by Secrest, R. J. Search for Related Content PubMed PubMed Citation Articles by Martino, S. Articles by Secrest, R. J.

The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials

^a The John Wayne Cancer Institute, St. Johns Health Center, Santa Monica, California, USA; ^b University of Pittsburgh, Pittsburgh, Pennsylvania, USA; ^c Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA; ^d Institute of Cancer Research, Parkside Oncology Clinic, London, United Kingdom

Correspondence: Roberta J. Secrest, Ph.D., Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. Telephone: 317-433-0032; Fax: 317-277-8165; e-mail: rsecrest{at}lilly.com

The role of estrogen in the development of breast cancer is well recognized, and the use of selective estrogen receptor modulators (SERMs) to reduce breast cancer risk continues to be evaluated. Tamoxifen is the only SERM approved for the reduction of breast cancer incidence in women at high risk. This approval was based on results from the Breast Cancer Prevention Trial. Although initial results from the Royal Marsden Hospital tamoxifen trial and Italian Tamoxifen Prevention Study did not show a similar overall effect of tamoxifen, recent updates from these two trials and initial results from the International Breast Cancer Intervention Study are consistent with a risk reduction effect of tamoxifen for estrogen-receptor-positive breast cancer.

Raloxifene, approved for the prevention and treatment of postmenopausal osteoporosis, is another SERM being evaluated for breast cancer risk reduction. The recently completed Continuing Outcomes Relevant to Evista^® trial and the Raloxifene Use for The Heart trial, have breast cancer risk reduction as a primary end point. A third, ongoing trial, the Study of Tamoxifen and Raloxifene trial, is evaluating the relative efficacy and adverse event profile of these two agents in a population at high risk. The study populations of these raloxifene breast cancer prevention trials and the four tamoxifen prevention trials are quite diverse in terms of breast cancer risk. Completion of these trials will provide important information about the occurrence of invasive breast cancer in postmenopausal women and the efficacy of raloxifene for breast cancer risk reduction.

Key Words. Breast cancer • Chemoprevention • Raloxifene • Selective estrogen receptor modulators • Tamoxifen

This article has been cited by other articles:

				J. M. Faupel-Badger, S. A. Prindiville, D. Venzon, B. K. Vonderhaar, J. A. Zujewski, and J. Eng-Wong Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1153 - 1158. [Abstract] [Full Text] [PDF]

				G. S. Daftary and H. S. Taylor Endocrine Regulation of HOX Genes Endocr. Rev., June 1, 2006; 27(4): 331 - 355. [Abstract] [Full Text] [PDF]

				G. E. Goodman, M. D. Thornquist, C. Edelstein, and G. S. Omenn Biorepositories: Let's Not Lose What We Have So Carefully Gathered! Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 599 - 601. [Full Text] [PDF]

				P. R. Hutson, R. R. Love, T. C. Havighurst, E. Rogers, and J. F. Cleary Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8722 - 8727. [Abstract] [Full Text] [PDF]